{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:29:19Z","timestamp":1768721359295,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Boryung Pharmaceutical Co, Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.clinthera.2012.04.021","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T01:15:48Z","timestamp":1337217348000},"page":"1273-1289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and Tolerability of Once-Daily Oral Fimasartan 20 to 240 mg\/d in Korean Patients with Hypertension: Findings from Two Phase II, Randomized, Double-Blind, Placebo-Controlled Studies"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00923611","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00937651","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Howard","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ju","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Bae","family":"Seung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Seok","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Won","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Joong","family":"Rim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon-Han","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.04.021_bib1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.12.116","article-title":"Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT(1)) antagonists","volume":"22","author":"Kim","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2012.04.021_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11533640-000000000-00000","article-title":"Fimasartan","volume":"11","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.04.021_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11593840-000000000-00000","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects","volume":"11","author":"Chi","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.04.021_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.HYP.25.1.37","article-title":"Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients","volume":"25","author":"Goldberg","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2012.04.021_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1527-3466.1995.tb00305.x","article-title":"Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist","volume":"13","author":"Criscione","year":"1995","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/j.clinthera.2012.04.021_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","article-title":"Angiotensin II type 1 receptor blockers","volume":"103","author":"Burnier","year":"2001","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.04.021_bib7","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1038\/sj.jhh.1000992","article-title":"Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?","volume":"14","author":"Kaplan","year":"2000","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2012.04.021_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1751-7176.2011.00518.x","article-title":"Angiotensin receptor blockers: pharmacology, efficacy, and safety","volume":"13","author":"Taylor","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2012.04.021_bib9","series-title":"Clinical Trial Guidance for Antihypertensive Agents","year":"2009"},{"key":"10.1016\/j.clinthera.2012.04.021_bib10","first-page":"3","article-title":"1983 metropolitan height and weight tables","volume":"64","year":"1983","journal-title":"Stat Bull Metrop Life Found"},{"key":"10.1016\/j.clinthera.2012.04.021_bib11","article-title":"Korean Good Clinical Practices Guideline","year":"2008"},{"key":"10.1016\/j.clinthera.2012.04.021_bib12","article-title":"Pharmaceutical Affairs Law. 9123","year":"2008"},{"key":"10.1016\/j.clinthera.2012.04.021_bib13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.jhh.1000821","article-title":"Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring","volume":"13","author":"Diamant","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clinthera.2012.04.021_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.HYP.29.2.659","article-title":"Determining the trough-to-peak ratio in parallel-group trials","volume":"29","author":"Staessen","year":"1997","journal-title":"Hypertension"},{"issue":"6 Pt 1","key":"10.1016\/j.clinthera.2012.04.021_bib15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/01.HYP.26.6.942","article-title":"The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs","volume":"26","author":"Staessen","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2012.04.021_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0197-2456(89)90027-5","article-title":"Designing clinical trials for two-sided multiple comparisons with a control","volume":"10","author":"Bristol","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2012.04.021_bib17","series-title":"Sample Size Calculations in Clinical Research","year":"2003"},{"key":"10.1016\/j.clinthera.2012.04.021_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00003495-199856050-00013","article-title":"Candesartan cilexetil","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"issue":"4 Pt 2","key":"10.1016\/j.clinthera.2012.04.021_bib19","first-page":"95S","article-title":"Clinical efficacy of eprosartan","volume":"19","author":"Weber","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.04.021_bib20","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J Hum Hypertens"},{"issue":"12 Pt 2","key":"10.1016\/j.clinthera.2012.04.021_bib21","doi-asserted-by":"crossref","first-page":"318S","DOI":"10.1016\/S0895-7061(97)00386-5","article-title":"Clinical overview of irbesartan: a new angiotensin II receptor antagonist","volume":"10","author":"Pouleur","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2012.04.021_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00003495-199754060-00007","article-title":"Irbesartan","volume":"54","author":"Gillis","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.04.021_bib23","first-page":"82","article-title":"Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension","volume":"2","author":"Mallion","year":"1996","journal-title":"Blood Press Suppl"},{"key":"10.1016\/j.clinthera.2012.04.021_bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-199855050-00011","article-title":"Eprosartan","volume":"55","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.04.021_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1592\/phco.20.3.130.34788","article-title":"Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists","volume":"20","author":"Song","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2012.04.021_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/01.HYP.25.6.1345","article-title":"A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension","volume":"25","author":"Gradman","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2012.04.021_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/08037059709086444","article-title":"Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension","volume":"6","author":"Ikeda","year":"1997","journal-title":"Blood Press"},{"key":"10.1016\/j.clinthera.2012.04.021_bib28","first-page":"229","article-title":"Once-daily telmisartan compared with enalapril in the treatment of hypertension","volume":"15","author":"Smith","year":"1998","journal-title":"Adv Therap"},{"key":"10.1016\/j.clinthera.2012.04.021_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.HYP.0000047512.58862.A9","article-title":"Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?","volume":"41","author":"Forclaz","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2012.04.021_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00129784-200707050-00004","article-title":"Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists","volume":"7","author":"Smith","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2012.04.021_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ajh\/3.2.151","article-title":"Some problems with antihypertensive drug studies in the context of the new guidelines","volume":"3","author":"Rose","year":"1990","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2012.04.021_bib33","article-title":"Points to consider on missing data","year":"2001"},{"key":"10.1016\/j.clinthera.2012.04.021_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ebmh.11.1.3-a","article-title":"Missing data and the trouble with LOCF","volume":"11","author":"Streiner","year":"2008","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.clinthera.2012.04.021_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1503\/cmaj.080820","article-title":"Does analysis using \u201clast observation carried forward\u201d introduce bias in dementia research?","volume":"179","author":"Molnar","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2012.04.021_bib36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.107.704023","article-title":"Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics","volume":"118","author":"Johnson","year":"2008","journal-title":"Circulation"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:06Z","timestamp":1758962946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812002858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0149291812002858"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Once-Daily Oral Fimasartan 20 to 240 mg\/d in Korean Patients with Hypertension: Findings from Two Phase II, Randomized, Double-Blind, Placebo-Controlled Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}